Local News

• Luna awarded NIH grant to apply nanotechnology to allergy treatment  Luna Innovations announces the award of a $1.6 million Research Project Grant (R01) from the National Institutes of Health (NIH) to investigate the use of fullerene-based nanomedicines as a pathway to treat allergies and other inflammatory diseases.
  Luna Innovations Incorporated July 22, 2008  
• Merck announces fourth quarter 2008 dividend  The Board of Directors of Merck & Co. declared a quarterly dividend of $0.38 per share on the Company's common stock for the fourth quarter of 2008.
  Merck & Co., Inc. July 22, 2008  
• Medicare act extending longstanding reimbursement policy for brachytherapy seeds enacted  Theragenics announced favorable developments in Medicare reimbursement policies related to brachytherapy. On July 15, 2008, the Medicare Improvements for Patients and Providers Act of 2008 was enacted into law.
  Theragenics Corporation July 21, 2008  
• Trimeris reports second quarter 2008 FUZEON(R) sales results  Trimeris announced net sales of FUZEON for the second quarter of 2008 were $38.3 million, down 38 percent from $62.0 million in the second quarter of 2007. Net sales of FUZEON in the U.S. and Canada for the second quarter of 2008 were $16.1 million, down 51 percent from the second quarter of 2007.
  Trimeris, Inc. July 21, 2008  
• Senate Appropriations Committee approves $2 billion for FDA  The Senate Appropriations Committee unanimously passed an appropriations markup measure Thursday, providing the FDA with a $2.04 billion fiscal 2009 budget. This amount is $324.6 million more than the agency initially received for fiscal 2008.
  FDAnews July 21, 2008  
• Wyeth Pearl River Facility earns OSHA VPP Star; 2,000th workplace recognized in U.S.  Wyeth announced that its manufacturing and research facility in Pearl River, N.Y., has earned the highest recognition for workplace safety and health from the U.S. Department of Labor's Occupational Safety and Health Administration (OSHA): the Voluntary Protection Programs (VPP) "star."
  Wyeth July 21, 2008  
• Insmed provides update on IPLEX(TM) programs  Insmed provided an update on the status of its IPLEX(TM) development program. Insmed's Phase 2 trial of IPLEX(TM) in Myotonic Muscular Dystrophy (MMD), which was initiated in December 2007, has seen a strong patient and physician interest and is now fully enrolled.
  Insmed, Inc. July 21, 2008  
• Boston Scientific announces results for second quarter ended June 30, 2008  Boston Scientific announced financial results for the second quarter ended June 30, 2008, as well as guidance for net sales and earnings per share (EPS) for the third quarter of 2008. For the second quarter, the company achieved net sales of $2.024 billion.
  Boston Scientific Corporation July 21, 2008  
• Teva to acquire Barr  Teva Pharmaceutical and Barr Pharmaceuticals announced today that they have signed a definitive agreement under which Teva will acquire Barr, the fourth largest generic drug company worldwide. Each share of Barr common stock will be converted into $39.90 in cash and 0.6272 Teva ADRs.
  Barr Pharmaceuticals, Inc. July 18, 2008  
• U.S. cancels test of experimental AIDS vaccine  Federal researchers dropped plans for a large-scale test of an experimental AIDS vaccine developed by the National Institutes of Health - the latest fallout from the failure last September of a similar candidate from drugmaker Merck that may have left some volunteers more vulnerable to HIV.
  San Francisco Chronicle July 18, 2008  Sabin Russell

   (next 10 articles)